Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALT

Altimmune Inc

May 10 • 04:00PM ET

7.22

Dollar change -0.50
Percentage change -6.48	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF LABU IWN VTWO VHT IWC DFAC VFMO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.59	Insider Own	1.02%	Shs Outstand	70.68M	Perf Week	-1.10%
Market Cap	511.90M	Forward P/E	-	EPS next Y	-1.60	Insider Trans	0.00%	Shs Float	70.17M	Perf Month	-14.05%
Income	-92.77M	PEG	-	EPS next Q	-0.36	Inst Own	63.44%	Short Float	31.79%	Perf Quarter	-30.84%
Sales	0.41M	P/S	1248.53	EPS this Y	5.68%	Inst Trans	10.67%	Short Ratio	4.90	Perf Half Y	167.41%
Book/sh	2.44	P/B	2.96	EPS next Y	-2.30%	ROA	-49.42%	Short Interest	22.31M	Perf Year	44.98%
Cash/sh	2.57	P/C	2.81	EPS next 5Y	-	ROE	-54.46%	52W Range	2.09 - 14.84	Perf YTD	-35.82%
Dividend Est.	-	P/FCF	-	EPS past 5Y	35.74%	ROI	-53.63%	52W High	-51.35%	Beta	0.10
Dividend TTM	-	Quick Ratio	16.55	Sales past 5Y	115.21%	Gross Margin	-	52W Low	245.45%	ATR (14)	0.66
Dividend Ex-Date	Jan 20, 2017	Current Ratio	16.55	EPS Y/Y TTM	8.40%	Oper. Margin	-21596.34%	RSI (14)	44.74	Volatility	8.55% 8.33%
Employees	59	Debt/Eq	0.00	Sales Y/Y TTM	-91.60%	Profit Margin	-22626.10%	Recom	1.50	Target Price	20.57
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	13.98%	Payout	-	Rel Volume	0.67	Prev Close	7.72
Sales Surprise	-	EPS Surprise	8.11%	Sales Q/Q	-76.19%	Earnings	May 09 BMO	Avg Volume	4.56M	Price	7.22
SMA20	-0.07%	SMA50	-17.24%	SMA200	16.76%	Trades		Volume	3,042,519	Change	-6.48%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-29-24	Downgrade	Guggenheim	Buy → Neutral
Jan-24-24	Initiated	Goldman	Neutral	$13
Mar-22-23	Downgrade	Goldman	Buy → Neutral	$20 → $6
Dec-01-22	Initiated	Goldman	Buy	$20
Dec-29-21	Resumed	Jefferies	Buy	$30
Jun-02-21	Initiated	H.C. Wainwright	Buy	$35
Feb-11-21	Initiated	Guggenheim	Buy	$36
Dec-14-20	Initiated	Jefferies	Buy	$25
Nov-12-20	Reiterated	B. Riley Securities	Buy	$31 → $28
Sep-25-20	Initiated	B. Riley FBR	Buy	$31
Aug-14-20	Initiated	Evercore ISI	Outperform
Jul-31-20	Initiated	Piper Sandler	Overweight	$80
Jul-28-20	Initiated	JMP Securities	Mkt Outperform	$50
Feb-24-20	Resumed	ROTH Capital	Buy	$13
Jul-19-19	Initiated	ROTH Capital	Buy	$8.30
Oct-09-17	Initiated	Piper Jaffray	Overweight	$6

Show Previous Ratings

Today 03:58PM	Altimmune, Inc. (NASDAQ:ALT) Q1 2024 Earnings Call Transcript (Insider Monkey) -6.48%
May-09-24 11:57AM	ALT Stock Earnings: Altimmune Beats EPS for Q1 2024 (InvestorPlace) +7.82%
07:00AM	Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
May-08-24 08:50AM	Altimmune, Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit (GlobeNewswire)
May-07-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
07:30AM	Loading…
May-02-24 07:30AM	Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024 (GlobeNewswire)
May-01-24 07:30AM	Altimmune to Participate at Two Upcoming Conferences (GlobeNewswire) +7.94%
Apr-25-24 05:24PM	Altimmune Statement on the Passing of Dr. Stephen Harrison (GlobeNewswire)
Mar-29-24 12:00PM	Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Mar-28-24 10:49AM	Altimmune, Inc. (NASDAQ:ALT) Q4 2023 Earnings Call Transcript (Insider Monkey) +14.51%
Mar-27-24 06:29PM	A Novo Nordisk competitor teased a weight loss drug that minimizes muscle loss seen in other drugs (Quartz)
11:53AM	ALT Stock Earnings: Altimmune Beats EPS for Q4 2023 (InvestorPlace)
07:58AM	Altimmune bails on hepatitis B after phase 2 data disappoint, quashing partnering plans (FierceBiotech.com)
07:00AM	Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-20-24 07:30AM	Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024 (GlobeNewswire) +6.86%
09:26AM	Loading…
Feb-26-24 09:26AM	Why Is Altimmune (ALT) Stock Up 14% Today? (InvestorPlace) +23.04%
Feb-20-24 10:26AM	Altimmune (ALT) to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-13-24 03:07PM	Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report (InvestorPlace) -18.65%
Jan-02-24 07:30AM	Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024 (GlobeNewswire) -6.49%
Dec-01-23 11:45AM	Why Is Altimmune (ALT) Stock Up 43% Today? (InvestorPlace) +12.97%
04:47AM	Altimmune, seeking edge on Lilly and Novo, puts heart health at center of phase 2 obesity data drop (FierceBiotech.com)
Nov-30-23 04:24PM	Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide (GlobeNewswire)
Nov-08-23 09:15AM	Altimmune, Inc. (NASDAQ:ALT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 07:00AM	Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Oct-31-23 07:30AM	Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023 (GlobeNewswire)
Oct-26-23 07:30AM	Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH) (GlobeNewswire)
Oct-25-23 07:30AM	Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting 2023 (GlobeNewswire)
Oct-17-23 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Sep-26-23 07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Sep-12-23 07:30AM	Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight (GlobeNewswire) +7.41%
07:30AM	Loading…
Aug-30-23 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-03-23 07:30AM	Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023 (GlobeNewswire)
Aug-01-23 07:30AM	Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH) (GlobeNewswire)
Jun-27-23 09:56AM	These 2 Strong Buy Penny Stocks Could Soar to $25 (Or Higher), Says Piper Sandler (TipRanks) +6.96%
Jun-16-23 07:30AM	Altimmune to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th, 2023 (GlobeNewswire)
Jun-15-23 07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress 2023 (GlobeNewswire)
May-31-23 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
May-11-23 07:00AM	Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) +7.03%
May-08-23 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
May-04-23 07:30AM	Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 (GlobeNewswire)
Apr-11-23 07:30AM	Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell, an Immunotherapeutic for Chronic Hepatitis B (GlobeNewswire)
Mar-27-23 04:05PM	Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors (GlobeNewswire) +11.57%
Mar-21-23 07:00AM	Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial (GlobeNewswire) -54.67%
Feb-28-23 07:00AM	Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update (GlobeNewswire) +6.42%
Feb-21-23 07:30AM	Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023 (GlobeNewswire) -5.27%
Jan-04-23 07:30AM	Altimmune Appoints Raymond Jordt as Chief Business Officer (GlobeNewswire) -5.25%
07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023 (GlobeNewswire)
Dec-20-22 07:00AM	Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD) (GlobeNewswire) +15.98%
Nov-22-22 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire) +6.52%
Nov-10-22 07:00AM	Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update (GlobeNewswire) +9.18%
Nov-03-22 07:30AM	Altimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10 (GlobeNewswire)
Oct-28-22 07:30AM	Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting® (GlobeNewswire)
Sep-28-22 07:30AM	Altimmune Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight (GlobeNewswire) +13.25%
Sep-14-22 07:00AM	Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD (GlobeNewswire) -27.04%
Aug-11-22 07:00AM	Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update (GlobeNewswire) +7.08%
Aug-04-22 07:30AM	Altimmune to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11 (GlobeNewswire)
Jul-07-22 08:17AM	Will Altimmune (NASDAQ:ALT) Spend Its Cash Wisely? (Simply Wall St.) +7.92%
Jun-17-22 07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress on June 25, 2022 (GlobeNewswire) +22.89%
Jun-08-22 09:55AM	Wall Street Analysts Think Altimmune, Inc. (ALT) Could Surge 352%: Read This Before Placing a Bet (Zacks) +9.08%
May-31-22 07:30AM	Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022 (GlobeNewswire)
06:08AM	Insider Buying: The Altimmune, Inc. (NASDAQ:ALT) Independent Director Just Bought 6.6% More Shares (Simply Wall St.)
May-23-22 09:55AM	Wall Street Analysts See a 426% Upside in Altimmune, Inc. (ALT): Can the Stock Really Move This High? (Zacks)
May-20-22 07:30AM	Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022 (GlobeNewswire)
May-16-22 07:30AM	Altimmune to Present at Upcoming Investor Conferences (GlobeNewswire) -6.78%
May-14-22 09:51AM	Altimmune (NASDAQ:ALT) surges 19% this week, taking three-year gains to 111% (Simply Wall St.)
May-12-22 07:00AM	Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire) +8.63%
May-05-22 07:30AM	Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12 (GlobeNewswire) -6.21%
Apr-01-22 03:40PM	What Kind Of Investors Own Most Of Altimmune, Inc. (NASDAQ:ALT)? (Simply Wall St.)
07:00AM	Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity (GlobeNewswire)
Mar-22-22 12:47PM	The Biotech Sector Nears an Inflection Point; Analysts Offer 3 Stocks to Consider (TipRanks)
Mar-15-22 07:01AM	Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update (GlobeNewswire) -8.24%
Mar-08-22 07:00AM	Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022 (GlobeNewswire)
Feb-17-22 03:02PM	Analysts Estimate Altimmune, Inc. (ALT) to Report a Decline in Earnings: What to Look Out for (Zacks) -5.30%
Jan-31-22 07:00AM	Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity (GlobeNewswire) +12.08%
Jan-28-22 04:36AM	Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation (Simply Wall St.) +10.26%
Jan-24-22 02:48PM	It's been a tough year so far on Wall Street. These D.C.-area companies have suffered the biggest hits. (American City Business Journals)
Jan-03-22 07:00AM	Altimmune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022 (GlobeNewswire)
Dec-13-21 06:00AM	Altimmune Appoints Richard Eisenstadt as Chief Financial Officer (GlobeNewswire)
06:00AM	Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-22-21 04:01PM	Altimmune to Present at Upcoming Investor and Scientific Conferences (GlobeNewswire)
Nov-10-21 04:01PM	Altimmune to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-09-21 04:01PM	Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-03-21 04:01PM	Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021 (GlobeNewswire)
Nov-01-21 03:01PM	Altimmune, Inc. (ALT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-15-21 09:35PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT (PR Newswire)
Oct-13-21 04:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT (ACCESSWIRE)
Oct-11-21 03:51PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT (GlobeNewswire)
Oct-06-21 04:01PM	Altimmune to Present at Upcoming H.C. Wainwright Investor Conferences October 12-13, 2021 (GlobeNewswire)
Oct-04-21 07:00AM	Altimmune Announces Initiation of 12-week Phase 1b Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (GlobeNewswire) -5.27%
Oct-03-21 08:53PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT (GlobeNewswire)
Oct-01-21 05:15PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT (Newsfile) +5.66%
01:00PM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Altimmune, Inc. (ALT) Investigation (ACCESSWIRE)
Sep-29-21 06:15PM	Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 2021 (GlobeNewswire) -13.84%
Sep-28-21 07:01AM	Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers (GlobeNewswire)
05:00AM	Greater Washington's scientists recount the highs and lows of researching and testing Covid-19 vaccines (American City Business Journals)
Sep-27-21 04:01PM	Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021 (GlobeNewswire)
Sep-17-21 06:12AM	Shareholders Will Likely Find Altimmune, Inc.'s (NASDAQ:ALT) CEO Compensation Acceptable (Simply Wall St.) -7.07%
Sep-07-21 04:01PM	Altimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (GlobeNewswire)
Sep-02-21 06:21AM	Do Institutions Own Altimmune, Inc. (NASDAQ:ALT) Shares? (Simply Wall St.)

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Roberts M Scot	Chief Scientific Officer	Feb 02 '24	Option Exercise	0.00	7,775	0	44,990	Feb 05 06:02 PM
Harris Matthew Scott	Chief Medical Officer	Feb 02 '24	Option Exercise	0.00	7,775	0	55,965	Feb 05 06:01 PM
Garg Vipin K	President and CEO	Feb 02 '24	Option Exercise	0.00	18,950	0	300,404	Feb 05 06:00 PM
Garg Vipin K	President and CEO	Feb 01 '24	Option Exercise	0.00	16,545	0	288,767	Feb 05 06:00 PM
Harris Matthew Scott	Chief Medical Officer	Feb 01 '24	Option Exercise	0.00	6,166	0	49,991	Feb 05 06:01 PM
Roberts M Scot	Chief Scientific Officer	Feb 01 '24	Option Exercise	0.00	6,166	0	39,016	Feb 05 06:02 PM
Roberts M Scot	Chief Scientific Officer	Jan 30 '24	Option Exercise	0.00	9,275	0	29,699	Feb 01 06:03 PM
Garg Vipin K	President and CEO	Jan 30 '24	Option Exercise	0.00	26,775	0	276,030	Feb 01 06:01 PM
Harris Matthew Scott	Chief Medical Officer	Jan 30 '24	Option Exercise	0.00	9,275	0	43,277	Feb 01 06:01 PM
Eisenstadt Richard I	Chief Financial Officer	Jan 30 '24	Option Exercise	0.00	9,275	0	42,566	Feb 01 06:00 PM
Jordt Raymond M	Chief Business Officer	Jan 01 '24	Option Exercise	0.00	9,375	0	11,207	Jan 04 06:00 PM
Eisenstadt Richard I	Chief Financial Officer	Dec 29 '23	Option Exercise	0.00	12,500	0	36,335	Jan 02 06:00 PM
Drutz David	Director	Aug 15 '23	Buy	2.88	300	862	29,785	Aug 15 06:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALT

Altimmune Inc

Upgrade your FINVIZ experience